Steatotic liver disease labels hinge on alcohol intake, but self-report is often inaccurate.

Can bacteria-free, sterile faecal filtrate match conventional faecal microbiota transplantation for recurrent C difficile infection? Dina Kao unpacks a landmark multicentre trial that tested this hypothesis, and we discuss what it tells us about the role of living organisms in the therapeutic effects of microbiota-based therapies

Do wheat or gluten trigger IBS symptoms? We spoke to Premysl Bercik about a randomised, double-blind, sham-controlled crossover trial that challenged adults with IBS—who reported benefit from a gluten-free diet—with wheat, gluten, or a gluten-free sham to test symptom and behavioural responses.

Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.

How does acute kidney injury presentation and management differ globally for patients hospitalised with cirrhosis? We spoke to Salvatore Piano, corresponding author of the landmark International Club of Ascites GLOBAL AKI study, about new data on regional variations in severity, phenotype, treatment, and outcomes across 5 continents.

John Chia discusses the results of the ASCOLT trial, which explored the effect of aspirin after completion of standard adjuvant therapy for patients with colorectal cancer.

Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.

Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease.

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.